U.S. markets open in 2 hours 56 minutes

Siemens Healthineers AG (SHL.MU)

Munich - Munich Delayed Price. Currency in EUR
54.80+1.08 (+2.01%)
As of 08:02AM CET. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close53.72
Bid54.60 x 0
Ask54.62 x 0
Day's Range54.80 - 54.80
52 Week Range44.87 - 57.84
Avg. Volume102
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateMay 07, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for SHL.MU

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • The Wall Street Journal

      Heard on the Street: Philips Struggles to Draw a Line Under Its Sleep-Apnea Crisis

      Dutch healthcare-equipment maker [Royal Philips just announced a long-awaited deal with U.S. authorities]( over its scandal-struck sleep-apnea machines. The explanation is that the settlement didn’t bring the kind of clarity on the future of Philips’ respiratory business that investors might have hoped for. Under the terms of a provisional agreement with the Food and Drug Administration, it won’t be allowed to sell its sleep-apnea machines in the U.S. until it meets undisclosed requirements.

    • Business Wire

      Siemens Healthineers launches Atellica CI Analyzer, compact testing system to tackle lab challenges

      TARRYTOWN, N.Y., July 20, 2023--The newest addition to the Siemens Healthineers Atellica in vitro diagnostics portfolio, the Atellica CI Analyzer1 for immunoassay and clinical chemistry testing, has received FDA clearance and is now available in many of the world’s major markets. Labs operating at low to medium testing volumes will benefit from competitive advantages that the analyzer offers, including improved turnaround time predictability, advanced reporting functionality, and focused safety

    • PR Newswire

      RS Abdi Waluyo acquires the world's first photon-counting CT to improve clinical outcomes for patients in Indonesia

      RS Abdi Waluyo located in Jakarta will be the first hospital in Indonesia to acquire the NAEOTOM Alpha, the world's first photon-counting CT with the aim to optimise diagnostic and treatment pathways for patients in the country.